RecombinantRabMAb

Recombinant Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)

Submit a review Submit a question
Western blot - Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)
  • Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR4157] to AKT1 (phospho T450) - BSA and Azide free
  • Suitable for: WB, IHC-P
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free
    See all AKT1 primary antibodies

  • Description

    Rabbit monoclonal [EPR4157] to AKT1 (phospho T450) - BSA and Azide free

  • Host species

    Rabbit

  • Specificity

    This antibody only detects AKT1 phosphorylated at threonine 450. 

  • Tested applications

    Suitable for: WB, IHC-Pmore details
    Unsuitable for: Flow Cyt or ICC

  • Species reactivity

    Reacts with: Mouse, Rat, Human

  • Immunogen

    Synthetic peptide within Human AKT1 (phospho T450). The exact sequence is proprietary.

  • General notes

    Ab247614 is the carrier-free version of ab108266. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    ab247614 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

    Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

    We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

    In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

    We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

    Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

    Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

Properties

Applications

Our Abpromise guarantee covers the use of ab247614 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Detects a band of approximately 60 kDa (predicted molecular weight: 56 kDa).
IHC-P Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Antigen retrieval is recommended.

 
  • Application notes
    Is unsuitable for Flow Cyt or ICC.

    • Target

    • Function

      Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. The activated form can suppress FoxO gene transcription and promote cell cycle progression. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly.

    • Tissue specificity

      Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.

    • Involvement in disease

      Defects in AKT1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
      Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].
      Defects in AKT1 are associated with susceptibility to ovarian cancer [MIM:604370]; also called susceptibility to familial breast-ovarian cancer type 1 (BROVCA1).

    • Sequence similarities

      Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.
      Contains 1 AGC-kinase C-terminal domain.
      Contains 1 PH domain.
      Contains 1 protein kinase domain.

    • Domain

      Binding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI(3)K) results in its targeting to the plasma membrane. The PH domain mediates interaction with TNK2 and Tyr-176 is also essential for this interaction.
      The AGC-kinase C-terminal mediates interaction with THEM4.

    • Post-translational
      modifications

      Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for full activity. Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to the anionic plasma membrane phospholipid PA. This phosphorylated form localizes to the cell membrane, where it is targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and Ser-473 leading to its activation. Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focal cortical dysplasias with Taylor-type balloon cells.
      Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination is critical for phosphorylation and activation. When ubiquitinated, it translocates to the plasma membrane, where it becomes phosphorylated. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome.

    • Cellular localization

      Cytoplasm. Nucleus. Cell membrane. Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus.
    • Information by UniProt

    • Database links

      see all

    • Alternative names

      • AKT 1 antibody
      • AKT antibody
      • AKT1 antibody
      • AKT1_HUMAN antibody
      • C AKT antibody
      • cAKT antibody
      • MGC99656 antibody
      • PKB alpha antibody
      • PKB antibody
      • PKB-ALPHA antibody
      • PRKBA antibody
      • Protein Kinase B Alpha antibody
      • Protein kinase B antibody
      • Proto-oncogene c-Akt antibody
      • RAC Alpha antibody
      • RAC antibody
      • Rac protein kinase alpha antibody
      • RAC Serine/Threonine Protein Kinase antibody
      • RAC-alpha serine/threonine-protein kinase antibody
      • RAC-PK-alpha antibody
      • v akt murine thymoma viral oncogene homolog 1 antibody
      • vAKT Murine Thymoma Viral Oncogene Homolog 1 antibody
      see all

    Images

    • Western blot - Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)
      Western blot - Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)
      All lanes : Anti-AKT1 (phospho T450) antibody [EPR4157] (ab108266) at 1/1000 dilution

      Lane 1 : NIH3T3 cell lysate, untreated
      Lane 2 : NIH3T3 cell lysate, treated with Lambda Phosphatase.

      Lysates/proteins at 10 µg per lane.

      Predicted band size: 56 kDa
      Observed band size: 60 kDa
      why is the actual band size different from the predicted?



      This data was developed using ab108266, the same antibody clone in a different buffer formulation.

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)
      Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)
      This data was developed using ab108266, the same antibody clone in a different buffer formulation.ab108266 at 1/50 dilution staining AKT1 in Human breast carcinom by Immunohistochemistry, Paraffin-embedded tissue. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
    • Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)
      Anti-AKT1 (phospho T450) antibody [EPR4157] - BSA and Azide free (ab247614)

    Protocols

    To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

    Click here to view the general protocols

    References (0)

    Publishing research using ab247614? Please let us know so that we can cite the reference in this datasheet.

    ab247614 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab247614.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com